ArticleJournal of Ayurveda and integrative medicine2026
Pathophysiological modulations by Trimad, a polyherbal formulation, in a rat model of high-fat diet-induced obesity.
Article in Journal of Ayurveda and integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is the most prevalent metabolic disorder globally, characterized by oxidative stress and inflammation that play a key role in its pathogenesis. Current anti-obesity drugs have adverse effects and fail to address oxidative stress and inflammation. Therefore, there is a growing need for safe and effective therapies. Ayurveda recommends Trimad for obesity management. Trimad is a polyherbal formulation consisting of Cyperus rotundus tubers (Musta), Embelia ribes fruits (Vidang), and Plumbago zeylanica roots (Chitraka) in an equal 1:1:1 ratio.
objectiveThis study evaluated the effect of Trimad on ameliorating pathophysiological changes in a rat model of high-fat diet (HFD)-induced obesity. MATERIAL AND
methodsMale wistar rats were divided into six groups (n = 6; IAEC approval no. BVDUMC/3293/2016/007/002). Group 1 served as the Normal control (normal chow diet), Group 2 as Disease control (HFD), Group 3 as Positive control (HFD + Atorvastatin, 1.2 mg/kg), and Groups 4-6 received HFD with Trimad extract at 50, 100, and 200 mg/kg, respectively for 48 days with treatment starting from day 24. Body weight, feed intake, biochemical parameters, oxidative stress markers, inflammatory cytokines, adipokines, adipocyte morphology, brain monoamines and hepatic lipid-metabolizing gene expression were evaluated.
resultsHFD caused lipid abnormalities, inflammation, oxidative stress, hepatic steatosis, and weight gain. Trimad significantly reduced weight gain, improved lipid metabolism by modulating hepatic lipid-metabolizing genes, and normalized biochemical parameters, oxidative stress, inflammatory markers, adipokines, and adipocyte hypertrophy. There was normalization of brain monoamines in Trimad treated groups.
conclusionTrimad effectively ameliorated HFD-induced obesity and demonstrated strong anti-obesity potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.